Drugs / JYP0322
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06128148 | May 2022 → Jun 2026 overdue | brain neoplasm, lung neoplasm | Guangzhou JOYO Pharma Co., Ltd | Recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07816380 | Oct 2026 → Dec 2028 expected | non-small cell lung carcinoma | Guangzhou JOYO Pharma Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07154368 | Sep 2025 → Oct 2027 expected | non-small cell lung carcinoma | Guangzhou JOYO Pharma Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JYP0322 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06128148 ↗ |
| Action | Inhibit | “JYP0322 is an orally available inhibitor of ROS1 (coded by the gene ROS1).” NCT06128148 ↗ |
| Route | Oral | “JYP0322 is administered orally at a dose of 50 mg qd for a specified duration until unacceptable toxicity, disease progression, or study completion.” NCT06128148 ↗ |
| Target | ROS1 | “JYP0322 is an orally available inhibitor of ROS1 (coded by the gene ROS1).” NCT06128148 ↗ |